These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 736583)

  • 1. Fate of pemphigus antibody following successful therapy. Preliminary evaluation of pemphigus antibody determinations to regulate therapy.
    O'Loughlin S; Goldman GC; Provost TT
    Arch Dermatol; 1978 Dec; 114(12):1769-72. PubMed ID: 736583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy of pemphigus.
    Bystryn JC
    Arch Dermatol; 1984 Jul; 120(7):941-51. PubMed ID: 6375579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopathological examination of esophagus as a useful criterion of cure in pemphigus vulgaris.
    Torzecka JD; Sysa-Jedrzejowska A; Waszczykowska E; Wozniacka A; Dziankowska-Bartkowiak B; Narbutt J
    J Eur Acad Dermatol Venereol; 1999 Mar; 12(2):115-8. PubMed ID: 10343938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of direct immunofluorescence in predicting remission in pemphigus vulgaris.
    Balighi K; Taheri A; Mansoori P; Chams C
    Int J Dermatol; 2006 Nov; 45(11):1308-11. PubMed ID: 17076711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of pemphigus in pediatric patients.
    Gürcan H; Mabrouk D; Razzaque Ahmed A
    Minerva Pediatr; 2011 Aug; 63(4):279-91. PubMed ID: 21909064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
    Morrison LH
    J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine therapy should be considered for maintenance of remission in patients with pemphigus.
    Vardy DA; Cohen AD
    Arch Dermatol; 2001 Apr; 137(4):505-6. PubMed ID: 11295940
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
    Ahmed AR
    J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged remission after immunosuppressive therapy in six dogs with pemphigus foliaceus.
    Olivry T; Bergvall KE; Atlee BA
    Vet Dermatol; 2004 Aug; 15(4):245-52. PubMed ID: 15305932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption.
    Shimanovich I; Herzog S; Schmidt E; Opitz A; Klinker E; Bröcker EB; Goebeler M; Zillikens D
    Clin Exp Dermatol; 2006 Nov; 31(6):768-74. PubMed ID: 16824051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
    Arin MJ; Engert A; Krieg T; Hunzelmann N
    Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N; Qureshi A; Ahmed AR
    Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin.
    Mashkilleyson N; Mashkilleyson AL
    Acta Derm Venereol; 1988; 68(5):413-21. PubMed ID: 2461025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies.
    Tan-Lim R; Bystryn JC
    J Am Acad Dermatol; 1990 Jan; 22(1):35-40. PubMed ID: 2298963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.
    Abasq C; Mouquet H; Gilbert D; Tron F; Grassi V; Musette P; Joly P
    Arch Dermatol; 2009 May; 145(5):529-35. PubMed ID: 19451496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
    Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
    Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
    Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
    Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of pemphigus. Critical remarks based on 44 clinical cases].
    Smolle J
    Hautarzt; 1985 Feb; 36(2):96-102. PubMed ID: 2985524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases.
    Mahajan VK; Sharma NL; Sharma RC; Garg G
    Int J Dermatol; 2005 Oct; 44(10):821-7. PubMed ID: 16207182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunodepressants in the overall therapy of pemphigus].
    Kalamkarian AA; Trofimova LIa; Khapilova VI
    Vestn Dermatol Venerol; 1979 Dec; (12):28-32. PubMed ID: 525019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.